A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia

ClinicalTrials.gov Identifier: NCT05445323; Sponsor: Lexeo Therapeutics

Intervention/treatment: 

Genetic: Low dose LX2006 Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN) Genetic: High Dose LX2006 Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)